Leukocyte and platelet lowering by some interferon types during viral hepatitis treatment

Fabrizio Toccaceli, Silvia Rosati, Massimiliano Scuderi, Fabio Lacomi, Rattaele Picconi, Vittorio Laghi, Maria Grimaldi

Research output: Contribution to journalArticle

Abstract

BACKGROUND/AIMS: The hematologic toxicity (leukothrombocytopenia) of interferon therapy is well known and frequently observed; it may vary, however, according to the type of interferon administered. METHODOLOGY: We retrospectively assessed 158 patients with chronic viral hepatitis treated for 6-12 months with alpha (recombinant, lymphoblastoid or leukocyte) or beta interferon to monitor leukothrombocytopenia. RESULTS: During treatment, a significant decrease in leukocyte and platelet counts was detected in 48% and 43% of patients, respectively. The maximum decrease (31% and 26% of pre-treatment values; p <0.01) occurred after 4.9 and 4.2 months of treatment. No patient showed clinical symptoms of leukopenia or thrombocytopenia. Beta-interferon yielded the smallest decreases in leukocyte and platelet counts (-21% and -16% of pre-treatment values, respectively). Among alpha interferons, the lymphoblastoid (9 MU/week) produced the largest decrease both in leukocyte (38%; p <0.05 vs any other type) and in platelet (32%) number. The same dose of leukocyte interferon had the smallest effect (leukocytes: -27%; platelets: -2%), while recombinant interferon showed intermediate toxicity (-32% and -26% respectively). CONCLUSIONS: From this retrospective study, the hematologic toxicity of α and α interferons usually emerges as mild. However, leukopenia and thrombocytopenia may be induced more frequently by some of these interferon types.

Original languageEnglish
Pages (from-to)1748-1752
Number of pages5
JournalHepato-Gastroenterology
Volume45
Issue number23
Publication statusPublished - 1998

Fingerprint

Interferons
Hepatitis
Leukocytes
Blood Platelets
Platelet Count
Interferon-alpha
Interferon-beta
Leukopenia
Leukocyte Count
Thrombocytopenia
Therapeutics
Chronic Hepatitis
Retrospective Studies

Keywords

  • Chronic hepatitis
  • Interferon
  • Interferon α
  • Leukopenia
  • Thrombocytopenia

ASJC Scopus subject areas

  • Gastroenterology

Cite this

Toccaceli, F., Rosati, S., Scuderi, M., Lacomi, F., Picconi, R., Laghi, V., & Grimaldi, M. (1998). Leukocyte and platelet lowering by some interferon types during viral hepatitis treatment. Hepato-Gastroenterology, 45(23), 1748-1752.

Leukocyte and platelet lowering by some interferon types during viral hepatitis treatment. / Toccaceli, Fabrizio; Rosati, Silvia; Scuderi, Massimiliano; Lacomi, Fabio; Picconi, Rattaele; Laghi, Vittorio; Grimaldi, Maria.

In: Hepato-Gastroenterology, Vol. 45, No. 23, 1998, p. 1748-1752.

Research output: Contribution to journalArticle

Toccaceli, F, Rosati, S, Scuderi, M, Lacomi, F, Picconi, R, Laghi, V & Grimaldi, M 1998, 'Leukocyte and platelet lowering by some interferon types during viral hepatitis treatment', Hepato-Gastroenterology, vol. 45, no. 23, pp. 1748-1752.
Toccaceli F, Rosati S, Scuderi M, Lacomi F, Picconi R, Laghi V et al. Leukocyte and platelet lowering by some interferon types during viral hepatitis treatment. Hepato-Gastroenterology. 1998;45(23):1748-1752.
Toccaceli, Fabrizio ; Rosati, Silvia ; Scuderi, Massimiliano ; Lacomi, Fabio ; Picconi, Rattaele ; Laghi, Vittorio ; Grimaldi, Maria. / Leukocyte and platelet lowering by some interferon types during viral hepatitis treatment. In: Hepato-Gastroenterology. 1998 ; Vol. 45, No. 23. pp. 1748-1752.
@article{9c80898fa2a2426e8874ff2376084371,
title = "Leukocyte and platelet lowering by some interferon types during viral hepatitis treatment",
abstract = "BACKGROUND/AIMS: The hematologic toxicity (leukothrombocytopenia) of interferon therapy is well known and frequently observed; it may vary, however, according to the type of interferon administered. METHODOLOGY: We retrospectively assessed 158 patients with chronic viral hepatitis treated for 6-12 months with alpha (recombinant, lymphoblastoid or leukocyte) or beta interferon to monitor leukothrombocytopenia. RESULTS: During treatment, a significant decrease in leukocyte and platelet counts was detected in 48{\%} and 43{\%} of patients, respectively. The maximum decrease (31{\%} and 26{\%} of pre-treatment values; p <0.01) occurred after 4.9 and 4.2 months of treatment. No patient showed clinical symptoms of leukopenia or thrombocytopenia. Beta-interferon yielded the smallest decreases in leukocyte and platelet counts (-21{\%} and -16{\%} of pre-treatment values, respectively). Among alpha interferons, the lymphoblastoid (9 MU/week) produced the largest decrease both in leukocyte (38{\%}; p <0.05 vs any other type) and in platelet (32{\%}) number. The same dose of leukocyte interferon had the smallest effect (leukocytes: -27{\%}; platelets: -2{\%}), while recombinant interferon showed intermediate toxicity (-32{\%} and -26{\%} respectively). CONCLUSIONS: From this retrospective study, the hematologic toxicity of α and α interferons usually emerges as mild. However, leukopenia and thrombocytopenia may be induced more frequently by some of these interferon types.",
keywords = "Chronic hepatitis, Interferon, Interferon α, Leukopenia, Thrombocytopenia",
author = "Fabrizio Toccaceli and Silvia Rosati and Massimiliano Scuderi and Fabio Lacomi and Rattaele Picconi and Vittorio Laghi and Maria Grimaldi",
year = "1998",
language = "English",
volume = "45",
pages = "1748--1752",
journal = "Acta hepato-splenologica",
issn = "0172-6390",
publisher = "H.G.E. Update Medical Publishing Ltd.",
number = "23",

}

TY - JOUR

T1 - Leukocyte and platelet lowering by some interferon types during viral hepatitis treatment

AU - Toccaceli, Fabrizio

AU - Rosati, Silvia

AU - Scuderi, Massimiliano

AU - Lacomi, Fabio

AU - Picconi, Rattaele

AU - Laghi, Vittorio

AU - Grimaldi, Maria

PY - 1998

Y1 - 1998

N2 - BACKGROUND/AIMS: The hematologic toxicity (leukothrombocytopenia) of interferon therapy is well known and frequently observed; it may vary, however, according to the type of interferon administered. METHODOLOGY: We retrospectively assessed 158 patients with chronic viral hepatitis treated for 6-12 months with alpha (recombinant, lymphoblastoid or leukocyte) or beta interferon to monitor leukothrombocytopenia. RESULTS: During treatment, a significant decrease in leukocyte and platelet counts was detected in 48% and 43% of patients, respectively. The maximum decrease (31% and 26% of pre-treatment values; p <0.01) occurred after 4.9 and 4.2 months of treatment. No patient showed clinical symptoms of leukopenia or thrombocytopenia. Beta-interferon yielded the smallest decreases in leukocyte and platelet counts (-21% and -16% of pre-treatment values, respectively). Among alpha interferons, the lymphoblastoid (9 MU/week) produced the largest decrease both in leukocyte (38%; p <0.05 vs any other type) and in platelet (32%) number. The same dose of leukocyte interferon had the smallest effect (leukocytes: -27%; platelets: -2%), while recombinant interferon showed intermediate toxicity (-32% and -26% respectively). CONCLUSIONS: From this retrospective study, the hematologic toxicity of α and α interferons usually emerges as mild. However, leukopenia and thrombocytopenia may be induced more frequently by some of these interferon types.

AB - BACKGROUND/AIMS: The hematologic toxicity (leukothrombocytopenia) of interferon therapy is well known and frequently observed; it may vary, however, according to the type of interferon administered. METHODOLOGY: We retrospectively assessed 158 patients with chronic viral hepatitis treated for 6-12 months with alpha (recombinant, lymphoblastoid or leukocyte) or beta interferon to monitor leukothrombocytopenia. RESULTS: During treatment, a significant decrease in leukocyte and platelet counts was detected in 48% and 43% of patients, respectively. The maximum decrease (31% and 26% of pre-treatment values; p <0.01) occurred after 4.9 and 4.2 months of treatment. No patient showed clinical symptoms of leukopenia or thrombocytopenia. Beta-interferon yielded the smallest decreases in leukocyte and platelet counts (-21% and -16% of pre-treatment values, respectively). Among alpha interferons, the lymphoblastoid (9 MU/week) produced the largest decrease both in leukocyte (38%; p <0.05 vs any other type) and in platelet (32%) number. The same dose of leukocyte interferon had the smallest effect (leukocytes: -27%; platelets: -2%), while recombinant interferon showed intermediate toxicity (-32% and -26% respectively). CONCLUSIONS: From this retrospective study, the hematologic toxicity of α and α interferons usually emerges as mild. However, leukopenia and thrombocytopenia may be induced more frequently by some of these interferon types.

KW - Chronic hepatitis

KW - Interferon

KW - Interferon α

KW - Leukopenia

KW - Thrombocytopenia

UR - http://www.scopus.com/inward/record.url?scp=0031767726&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031767726&partnerID=8YFLogxK

M3 - Article

C2 - 9840140

AN - SCOPUS:0031767726

VL - 45

SP - 1748

EP - 1752

JO - Acta hepato-splenologica

JF - Acta hepato-splenologica

SN - 0172-6390

IS - 23

ER -